WASHINGTON May 11 A U.S. appeals court upheld
a lower court ruling on Friday that blocked U.S. sales of two
copycat versions of the Johnson & Johnson (JNJ.N) antipsychotic
drug Risperdal until a J&J patent expires at the end of 2007.
The U.S. Court of Appeals for the Federal Circuit affirmed
rulings by a lower court judge in New Jersey that upheld the
validity of a key J&J patent on the drug and delayed the
effective date of a tentative approval given to Mylan
Pharmaceuticals Inc. , a unit of Mylan Laboratories Inc.
MYL.N to market its generic Risperdal.
Risperdal generated sales of about $3 billion in 2005.
A lawsuit filed by J&J unit Janssen LP in December 2003
alleged Mylan and India's Dr. Reddy's Laboratories Ltd.
(REDY.BO) infringed the Risperdal patent.
Risperdal was approved in 1993 and is marketed as a
treatment for schizophrenia, mania associated with manic
depression and irritability associated with autism in children